消化

订阅

MedSci主页 / 所有栏目 / 消化

Annal Onco：西妥昔单抗/吉西他滨/调强放疗（IMRT）新辅助化放疗治胰腺导管腺癌有效

2012-05-17 MedSci原创 MedSci原创

新辅助化放疗胰腺导管腺癌
关注

　　 　　《肿瘤学年鉴》（Annals of Oncology）近期发表的一项研究表明，西妥昔单抗/吉西他滨/调强放疗（IMRT）新辅助化疗对胰腺导管腺癌（PDAC）有疗效。 　　新辅助方案包括西妥昔单抗负荷剂量400 mg/m2，继以西妥昔单抗250 mg/m2/周和吉西他滨50 mg/m2每周2次，同步IMRT 54 G

　　 　　《肿瘤学年鉴》（Annals of Oncology）近期发表的一项研究表明，西妥昔单抗/吉西他滨/调强放疗（IMRT）新辅助化疗对胰腺导管腺癌（PDAC）有疗效。 　　新辅助方案包括西妥昔单抗负荷剂量400 mg/m2，继以西妥昔单抗250 mg/m2/周和吉西他滨50 mg/m2每周2次，同步IMRT 54 Gy。后续治疗为手术切除。 　　共有37例患者入组，其中33例可评估缓解情况。 　　10例（30%）部分缓解，20例（61%）疾病稳定。 　　25例（76%）接受了切除手术，23例（92%）手术切缘为阴性。 　　接受切除术的患者中位生存期为24.3个月。 　　表皮生长因子状态对患者转归无影响。 英文摘要： BACKGROUND: Neoadjuvant therapy has been investigated for localized and locally advanced pancreatic ductal adenocarcinoma (PDAC) but no standard of

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038192, encodeId=145e2038192dd, content=<a href='/topic/show?id=bad791999de' target=_blank style='color:#2F92EE;'>#调强放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91999, encryptionId=bad791999de, topicName=调强放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Feb 27 14:00:00 CST 2013, time=2013-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678462, encodeId=862216e846295, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Oct 20 08:00:00 CST 2012, time=2012-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679409, encodeId=71ba16e940947, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Nov 23 04:00:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
    2013-02-27 12498cbcm00(暂无昵称)

    #调强放疗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2038192, encodeId=145e2038192dd, content=<a href='/topic/show?id=bad791999de' target=_blank style='color:#2F92EE;'>#调强放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91999, encryptionId=bad791999de, topicName=调强放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Feb 27 14:00:00 CST 2013, time=2013-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678462, encodeId=862216e846295, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Oct 20 08:00:00 CST 2012, time=2012-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679409, encodeId=71ba16e940947, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Nov 23 04:00:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
    2012-10-20 charl1234576

    #新辅助#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2038192, encodeId=145e2038192dd, content=<a href='/topic/show?id=bad791999de' target=_blank style='color:#2F92EE;'>#调强放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91999, encryptionId=bad791999de, topicName=调强放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Feb 27 14:00:00 CST 2013, time=2013-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678462, encodeId=862216e846295, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Oct 20 08:00:00 CST 2012, time=2012-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679409, encodeId=71ba16e940947, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Nov 23 04:00:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
    2012-11-23 chengjn

    #西妥昔#

    0